Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gasperetti Alessio, Muller Steven A, Peretto Giovanni, Asatryan Babken, Protonotarios Alexandros, Laredo Mikael, Tarlet Pierre-Yves, Syrris Petros, Carrick Richard T, Murray Brittney, Tichnell Crystal, Scheel Paul, Gigli Marta, Yap Sing-Chien, Pilichou Kalliopi, Basso Cristina, Medo Kristen, Jason Max, Rossi Valentina A, Saguner Ardan M, Duru Firat, Abrams Dominic, Cadrin-Tourigny Julia, Targetti Mattia, Pieroni Maurizio, Graziosi Maddalena, Biagini Elena, Charron Philippe, Cox Moniek, Casella Michela, Tondo Claudio, Ware James S, Prasad Sanjay K, Calò Leonardo, Smith Eric, Ingles Jodie, Tandri Harikrishna, Ader Flavie, Peters Stacey, Zentner Dominica, Russo Jeremy, Ravaro Silvia, Crotti Lia, Dittmann Sven, Schulze-Bahr Eric, Carruth Eric D, Krysov Vikki A, Parikh Victoria N, Conte Giulio, Wilde Arthur, van Tintelen J Peter, Te Riele Anneline S J M, Sinagra Gianfranco, Mestroni Luisa, Taylor Matthew, Merlo Marco, Adamo Luigi, Calkins Hugh, Bauce Barbara, Arbelo Elena, Elliott Perry M, Gandjbakhch Estelle, Lakdawala Neal, Helms Adam, James Cynthia A, Gilotra Nisha A
Аннотация
METHODS: The study was designed as an observational cohort study using all patients with pathogenic or likely pathogenic DSP variants in the DSP-ERADOS Network (Desmopakin Specific Effort for a Rare Disease Outcome Study) enrolled at 31 institutions up until April 30, 2024. Survival from ventricular arrhythmia and heart failure end points and recurrent myocarditis-like episodes was evaluated for both first and recurrent documented myocarditis-like episodes and the impact of immunosuppressive treatment on outcomes assessed.
RESULTS: A total of 1014 patients with pathogenic or likely pathogenic DSP variants (62.4% female; mean age, 40.4±17.4 years; 47.1% probands) were included. Among them, 177 individuals (17.5%) experienced ≥1 documented myocarditis-like episode, with 63 of them (35.6%) receiving immunosuppressive treatment. Immunosuppressive treatment of the first documented myocarditis-like episode was associated with reduced risk of ventricular arrhythmia and heart failure outcomes (hazard ratio, 0.18 [95% CI, 0.07-0.45]; P<0.001; and hazard ratio, 0.09 [95% CI, 0.02-0.39; P=0.001, respectively) over a median follow-up of 6.4 years (95% CI, 4.0-10.5). This risk was comparable to that of patients with no history of myocarditis-like episode but did not correlate with a reduction in recurrent episodes after completion of initial immunosuppression (hazard ratio, 0.85 [95% CI, 0.47-1.54]; P=0.599). In contrast, nonsteroidal anti-inflammatory drugs or colchicine treatment did not influence outcomes.
CONCLUSIONS: Immunosuppressive treatment of myocarditis-like episodes in DSP patients was associated with improved combined ventricular arrhythmia or heart failure outcomes, supporting future prospective evaluation in DSP cohorts.